Ipamorelin, sometimes also written as „ipamoreline”, is a lab-designed peptide with the chemical structure Aib-His-D-2-Nal-D-Phe-Lys-NH2. This means it is built from a specific sequence of five amino acid building blocks, including several unusual, non-standard components not found in typical dietary proteins [1]. It was developed by researchers working to create a growth hormone-releasing compound. It emerged from a broader chemical program investigating a related family of peptides known as growth hormone-releasing peptides (GHRPs). Ipamorelin was specifically identified as a promising candidate after researchers removed a specific dipeptide segment from an earlier compound called GHRP-1 and refined the remaining structure [1].
In terms of basic classification, ipamorelin belongs to the category of compounds known as growth hormone secretagogues. This means that it works by stimulating the body's own pituitary gland to release growth hormone, rather than being growth hormone itself—a distinction discussed in more detail below.
What does Ipamorelin do?
At its core, ipamorelin stimulates the release of growth hormone from the pituitary gland. Foundational studies establishing this were conducted in both laboratory (in vitro) and animal (in vivo) settings before any human data existed. In early tests using isolated rat pituitary cells, ipamorelin released growth hormone with a potency and efficacy comparable to an already known compound called GHRP-6 [1]. When tested in live animals, first in anaesthetized rats, and then in conscious pigs, ipamorelin again elicited significant, dose-dependent increases in growth hormone release. The effects were generally similar in magnitude to GHRP-6 [1].
A particularly significant finding from these same foundational studies was that ipamorelin appeared to be clearly selective in what it affected. When researchers measured other pituitary-related hormones in pigs, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, and thyroid-stimulating hormone (TSH), none of them were significantly altered by ipamorelin treatment [1].
Perhaps most notably, related compounds such as GHRP-6 and GHRP-2 also increased ACTH and cortisol, hormones associated with the body's stress response. Ipamorelin, however, did not cause a significant increase in either – even at doses over 200 times the amount needed to elicit its growth hormone-releasing effect [1].
This combination of properties – effectively raising growth hormone while leaving several other hormonal systems largely untouched – prompted the original researchers to describe ipamorelin as the first GHRP-type compound with a level of selectivity comparable to growth hormone-releasing hormone (GHRH) itself [1].
Ipamorelin jest stosowany w leczeniu zespołu wyniszczenia, u pacjentów z AIDS oraz w leczeniu chorób, które powodują utratę masy mięśniowej, takich jak rak.
Based strictly on published, peer-reviewed research available to date, the most documented area of clinical human research for ipamorelin has actually been in a context quite different from what most people seeking it might expect: gastrointestinal recovery post-surgery. A multi-centre, randomised, placebo-controlled, Phase 2 clinical trial specifically tested ipamorelin, administered as an intravenous infusion twice daily, in adult patients recovering from bowel resection surgery. Researchers were evaluating whether it could expedite the return of normal digestive function, a common post-operative complication called paralytic ileus [2].
This link exists because the ghrelin receptor, which ipamorelin activates, also plays a documented role in gastrointestinal motility, not just in growth hormone release. This gave researchers a concrete clinical rationale to test it in the context of surgical recovery.
In addition to its post-operative application, ipamorelin has also been extensively studied in general growth hormone axis research. This includes investigating its effects on growth hormone and IGF-1 levels, bone formation, body composition in animal models, and its pharmacokinetic behaviour in human volunteers [1], [3].
It's important to be direct here. Despite this scope of research interest, ipamorelin has not received approval from the FDA or any comparable regulator for any of these uses, including its use in paralytic ileus, for which it was specifically tested. It remains classified as a research compound, not an approved drug. Uses discussed in fitness, anti-aging, or bodybuilding contexts go far beyond this basic, more narrowly researched clinical trial foundation.
Is Ipamorelin a Growth Hormone Releasing Peptide (GHRP)?
Yes, ipamorelin is classified as a growth hormone-releasing peptide (GHRP). This is a distinct category from growth hormone-releasing hormone (GHRH) analogues, such as CJC-1295. Understanding this distinction is key to understanding how ipamorelin actually works within the body.
Is Ipamorelin a GHRP or a GHRH?
Ipamorelin belongs to the GHRP family, not GHRH. This classification stems directly from its receptor target, not simply its nomenclature. In foundational pharmacological studies of ipamorelin, scientists employed specific blocking agents for both GHRP-type and GHRH-type receptors to ascertain which pathway ipamorelin actually acted through. The results clearly showed that ipamorelin, much like the already-known compound GHRP-6, stimulated growth hormone release via the „GHRP-like receptor,” not through a separate GHRH receptor pathway [1]. This GHRP-like receptor is more formally known today as the ghrelin receptor, or GHS-R1a (growth hormone secretagogue receptor type 1a). This is the same receptor that the naturally occurring hormone ghrelin activates, which is why ipamorelin is often and accurately described as a ghrelin mimetic or ghrelin receptor agonist [4].
Within the broader category of GHRPs, original research specifically singled out ipamorelin as unusually selective compared to earlier compounds such as GHRP-1, GHRP-2, and GHRP-6. This is based on its lack of significant effect on cortisol, ACTH, and several other pituitary hormones outlined above [1]. It is therefore often referred to in scientific literature as the „first selective growth hormone secretagogue”.
How Ipamorelin works - mechanism of action
The mechanism of ipamorelin focuses on binding and activating the ghrelin receptor (GHS-R1a). This receptor is primarily found on growth hormone-producing cells, known as somatotrophs, in the anterior pituitary gland, as well as in the hypothalamic region of the brain that helps regulate the broader growth hormone system [4]. A detailed scientific review of how growth hormone secretagogues integrate with the body's natural ghrelin system has clarified something significant. This receptor system doesn't simply bypass the body's normal hormonal checks and balances. Instead, it appears to operate partly by helping to overcome certain inhibitory „brakes” that the body normally applies to growth hormone release. This includes partially overriding the inhibitory effects of both blood glucose and somatostatin, a major natural inhibitor of growth hormone secretion in the body [4].
The same review described the ghrelin receptor system as functioning as an amplifier for the separate GHRH signalling pathway. It works somewhat in parallel with it, rather than as a complete substitute. This helps to explain why GHRH analogues, such as CJC-1295, and ghrelin receptor agonists, such as ipamorelin, are often discussed together as working through complementary rather than redundant mechanisms [4].
It is worth being precise about what „desensitisation” or „inhibition” of somatostatin means in this context. Studies indicate that ipamorelin's pathway may partially bypass or reduce the inhibitory effect of somatostatin, rather than entirely eliminate somatostatin's regulatory role. This means the body's natural feedback loop remains at least partially intact, rather than being completely circumvented. This is an important distinction from directly injecting growth hormone itself, as direct administration of the hormone does not go through the same natural regulatory checkpoint at all.
Is Ipamorelin a Steroid, Growth Hormone, or Peptide?
To directly address a common point of confusion: ipamorelin is a peptide, not a steroid, and it is not human growth hormone (HGH) itself, though it is closely related to the growth hormone system as a whole. Structurally, it is a chain of five amino acids [1]. This places it in a completely different chemical category than anabolic-androgenic steroids, which are built from a steroid ring structure derived from cholesterol. The two have no significant structural or mechanistic overlap, and ipamorelin does not act on androgen receptors in the way anabolic steroids do.
It is not solely growth hormone itself. It is rather specifically classified as a growth hormone secretagogue – a compound that stimulates the body to release its own growth hormone from the pituitary gland, as opposed to introducing external, synthetic growth hormone directly into the bloodstream [1], [4].
Ipamorelin is also not a SARM (Selective Androgen Receptor Modulator), a separate class of compounds that act directly on androgen receptors in muscle and bone tissue. Ipamorelin's receptor target, the ghrelin receptor, is a completely different biological system than the androgen receptor pathway that SARMs engage with [4].
Similarly, ipamorelin is not a GLP-1 receptor agonist, a class of drugs that includes medications such as semaglutide, used for diabetes and weight management. GLP-1 drugs work through the incretin hormone system involved in blood sugar and appetite regulation – a pathway distinct from the ghrelin/growth hormone axis that ipamorelin engages with, even though both the ghrelin and GLP-1 systems have some role in appetite regulation more broadly.
Limitations of current evidence
The basic pharmacology of ipamorelin, including its ability to selectively raise growth hormone without significantly impacting cortisol, ACTH, and several other pituitary hormones, is well-documented by peer-reviewed animal studies and early human investigations [1]. Its most significant human clinical trial evidence base pertains specifically to post-operative gastrointestinal recovery [2]—a narrower and different application than the general wellness or performance aims often associated with the compound in informal contexts.
Its classification as a GHRP acting via the ghrelin receptor (GHS-R1a) is also well-established in the foundational pharmacological literature [1] and supported by broader mechanistic reviews of the ghrelin signalling system [4]. The precise extent to which ipamorelin's pathway remains subject to the body's natural somatostatin-based negative feedback regulation, versus a fuller bypass of this system, is described within mechanistic and review literature. However, it has not been isolated and quantified specifically for ipamorelin in a dedicated human study measuring precisely that question. Broader claims about what ipamorelin „does” for muscle, fat loss, sleep, or anti-ageing goals extend beyond this foundational base of clinical and mechanistic evidence and should be treated with appropriate caution.
Disclaimer
Ipamorelin is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use. This article is provided for general educational and informational purposes only, reflects the state of published scientific literature at the time of writing, and does not constitute medical advice. It is not manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. The research summarised in this article comes from early-stage pharmacology, animal studies, a small number of human clinical trials, and mechanistic reviews, and does not establish that ipamorelin is safe or effective for general human use, including for fitness, anti-aging, or bodybuilding purposes. Nothing in this article should be interpreted as a recommendation to use, source, or administer ipamorelin. It does not identify, recommend, or endorse any specific supplier, brand, or product. Anyone considering the use of ipamorelin or any other peptide should consult with a qualified, licensed healthcare professional before making any decisions.
References
[1] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[4] Veldhuis, J. D., & Bowers, C. Y. (2010). Integrating GHS into the ghrelin system. International Journal of Peptides, 2010, Article 879503. https://doi.org/10.1155/2010/879503